KromaTiD Blog2023-03-22T10:28:23-06:00

KromaTiD’s Dark Lab Files: A Blog

Natural Killer T (NKT) Cells in Cancer Immunotherapy

While T cells engineered with chimeric antigen receptors (CAR-T cells) have revolutionized the landscape of hematologic malignancy treatment, their efficacy against solid tumors remains limited. However, there is a promising alternative: Natural Killer T (NKT) cells. These innate-like T lymphocytes are unique contenders in [...]

Automating CAR-NK Cell Manufacturing

Acute myeloid leukemia (AML) is a neoplastic process characterized by its aggressive nature and limited treatment options. Too many AML patients are unable to achieve long-term remission with current therapies, fueling the search for novel strategies. CAR-NK cells offer a compelling solution, leveraging the [...]

February 16, 2024|Tags: , , |

SynNotch-CAR T Cells vs. Glioblastoma

Glioblastoma multiforme (GBM), the deadliest malignant brain tumor, also represents a large proportion of all cerebral neoplasms1. Despite strides in immunotherapy, including Chimeric Antigen Receptor (CAR)-T cells, challenges like on-target off-tumor toxicity, the blood-brain barrier, and the immunosuppressive tumor microenvironment (TME) have hindered progress. [...]

February 9, 2024|Tags: , , , |

Stony Brook Study on the Role of DNA Amplification in Cancer Chemoresistance Leverages KromaTiD dGH in-Site™ Technology

[Longmont, CO. February 6, 2024] —A Stony Brook University team of researchers led by Gábor Balázsi, PhD, has identified DNA amplification as a major cause of drug resistance in engineered mammalian cell lines and has identified a novel approach to overcome it in those [...]

February 7, 2024|Tags: , , , |

Me2SO-Free Cryopreservation Tailored for CAR-NK Cells

Adoptive cell therapies like those based on CAR-T cells have demonstrated remarkable success against several different cancer types, even in advanced cases. Targeted diagnoses include B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma. CAR-modified cell therapies based on [...]

February 2, 2024|Tags: , , |

Rareservoir: A Powerful Genomic Tool for Rare Disease Research

Despite significant strides in genetic research, we lack a clear understanding of whether many rare diseases may have genetic origins, and of what those origins may be. However, a powerful new metadata resource, called Rareservoir, provides a promising path forward toward potential breakthroughs. With [...]

January 26, 2024|Tags: , , , |


Go to Top